AXQ Capital’s Arbutus Biopharma ABUS Stock Holding History

AXQ Capital’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-18,545	Closed	-$57.3K	–	554
2025 Q2	$57.3K	Buy	+18,545	New	+$61.6K	0.02%	538

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AXQ Capital's ABUS Position: Q3 2025 in Review

AXQ Capital sold out of Arbutus Biopharma (ABUS) in Q3 2025, closing a stake of 18,545 shares — an estimated $57.3K sold.

AXQ Capital first reported a position in ABUS in Q2 2025 and held it in 1 quarter. The position peaked at $57.3K in Q2 2025. 166 funds tracked by Wall St. Rank hold ABUS as of Q3 2025.

AXQ Capital reported no remaining Arbutus Biopharma position as of Q3 2025 after selling out during the quarter.
AXQ Capital sold 18,545 Arbutus Biopharma shares in Q3 2025, an estimated $57.3K.
AXQ Capital first reported a position in Arbutus Biopharma in Q2 2025 and held it in 1 quarter.
AXQ Capital's Arbutus Biopharma position peaked at $57.3K in Q2 2025.
166 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2025.

Based on AXQ Capital's 13F filing for Q3 2025, filed 10 Nov 2025.